MRK Options Signal Upside Resistance at $134: Q2 Beat Masks Acquisition Drag, Targeting Breakout

• Merck (MRK) closes up 0.72% to $128.69, holding firmly above the 30-day moving average of $126.56.
• Heavy Put Open Interest at $124 and $116 creates a strong floor, while Call OI clusters at $134 and $132 act as immediate ceilings.
• Q2 revenue beat and raised sales guidance contrast with lowered EPS outlook due to Terns and Cidara acquisition charges.
• Put/Call ratio of 0.82 suggests underlying bullish sentiment, despite short-term bearish technical momentum.

Merck is navigating a fascinating dichotomy right now. On one hand, you have a company delivering robust top-line growth and raising its full-year revenue outlook. On the other, you have massive one-time charges clouding the earnings picture and some short-term technical weakness. It’s a classic case of “good news, bad news, what do we do?” Let’s look at the options market to see where the smart money is positioning itself for the week ahead.

The Options Floor and Ceiling

When you look at the options chain, the story is surprisingly clear. The market isn’t screaming panic; it’s pricing in a range-bound consolidation with a slight lean toward the upside.

Let’s talk about support first. The Put Open Interest is heavily concentrated at the $124 strike (1,135 contracts) for this Friday’s expiration, followed by $116 (842 contracts). This is your safety net. If MRK dips, these puts are likely being bought as hedges or speculative bets on a deeper correction that hasn’t happened yet. The fact that there is relatively low Put OI at the current price level ($128 has only 372 contracts) suggests traders aren’t aggressively betting on a crash right now. They see $124 as a line in the sand.

On the flip side, the Call Open Interest tells us where the resistance lies. For this Friday, the biggest clusters are at $134 (856 contracts) and $132 (706 contracts). These are the walls. If MRK tries to rally, expect sellers to step in at these strikes. The next Friday expiration shows even heavier Call OI at $133 (1,549 contracts) and $140 (1,097 contracts). This tells me that while the short-term move might be capped around $130-$134, the medium-term expectation is for a gradual climb toward $135-$140.

The Put/Call ratio for open interest is sitting at 0.825. In plain English, for every put contract, there are roughly 1.2 call contracts. This is a bullish signal. It means more capital is flowing into calls than puts, indicating that institutional players are positioning for upside, even if they are hedging their downside exposure at $124.

I didn’t see any significant block trades today. No whales made a splash. This suggests the current price action is driven by standard retail and institutional flow rather than a single large bet. That’s actually a good thing—it means the trend is organic, not artificial.

News Flow: Growth vs. Charges

The fundamental backdrop is a mixed bag, but the core business is healthy. Merck reported Q2 sales of $16.6 billion, beating estimates. Keytruda sales grew 5% to $8.4 billion, and the new QLEX formulation is already contributing $463 million. That’s a smart play to offset the 2028 patent cliff.

However, the bottom line is messy. The company took $2.31 per share in charges for Terns and $3.62 for Cidara. This lowered their non-GAAP EPS outlook to $2.66-$2.76. It’s a lot of cash to burn on acquisitions, but management is betting big on long-term pipeline diversification. The approval of LIPFENDRA for cholesterol and expanded uses for Keytruda in bladder cancer are positive catalysts.

Does this news support the options setup? Yes. The raised revenue guidance supports the bullish call positioning. The lowered EPS explains why the stock hasn’t exploded higher—it’s digesting the acquisition costs. The market is looking past the one-time charges to focus on the $66.3-$67.3 billion sales forecast. This fundamental strength backs the technical view that $124 is a strong support level.

Trading Opportunities: Where to Play

So, how do you trade this? The setup suggests a bullish bias with defined risk. The stock is in a short-term bearish trend but a long-term bullish one. We want to buy the dip or play the breakout.

For the stock, I’m looking for a pullback to the 30-day support zone.

• Entry Zone: Consider buying MRK shares near $126.50 if they retest the 30-day moving average. This aligns with the lower Bollinger Band sentiment and offers a good risk/reward ratio.
• Stop Loss: Place a stop below $124, where the massive Put Open Interest lies. If it breaks $124, the thesis is invalid.
• Target: The initial target is $130.50, which is the 30-day resistance level. A breakout above that opens the door to $134.

For options traders, here are specific setups based on the data:

1. Bull Call Spread (Short-Term): Buy the MRK20260807C128 and sell the MRK20260807C134. This leverages the high Call OI at $134 as resistance. You profit if MRK moves from $128 to $134 by Friday. It’s a defined-risk play on the immediate range.
2. Bull Call Spread (Medium-Term): Buy the MRK20260814C130 and sell the MRK20260814C135. The next Friday expiration has huge Call OI at $133 (1,549 contracts). This suggests the market expects MRK to test $133 by mid-August. Selling the $135 call caps your upside but funds the trade.
3. Hedge Strategy: If you own the stock, consider buying the MRK20260807P124. With 1,135 contracts open, this is the market’s chosen floor. It’s cheap insurance if the acquisition news causes a short-term sell-off.

Avoid selling naked calls at $134 unless you’re very confident in the breakdown. The volume is high, and the news is fundamentally positive. The path of least resistance is higher, but it will be bumpy.

Volatility on the Horizon

The MACD histogram is slightly negative (-0.138), and the RSI is at 65, which is healthy but nearing overbought territory. This confirms the short-term pullback we might see before the next leg up.

Merck is a long-term compounder right now. The acquisitions of Terns and Cidara are painful in the short term but necessary for the next decade. The options market agrees. They are buying calls, hedging at $124, and ignoring the earnings noise.

Keep an eye on $134. If MRK clears that level on high volume, the rally to $140 could be swift. Until then, stick to the range. Buy low near $126, sell high near $134. It’s a disciplined approach that lets the fundamentals do the heavy lifting while the options market provides the map.